An external ventricular drainage catheter impregnated with rifampicin, trimethoprim and triclosan, with extended activity against MDR Gram-negative bacteria:an in vitro and in vivo study by Bayston, Roger et al.
                          Bayston, R., Ashraf, W., Pelegrin, I., Fowkes, K., Bienemann, A. S.,
Singleton, W. G. B., & Scott, I. S. (2019). An external ventricular drainage
catheter impregnated with rifampicin, trimethoprim and triclosan, with
extended activity against MDR Gram-negative bacteria: an in vitro and in
vivo study. Journal of Antimicrobial Chemotherapy, 74(10), 2959-2964.
[dkz293]. https://doi.org/10.1093/jac/dkz293
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1093/jac/dkz293
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Oxford University
Press at https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkz293/5532147 . Please refer to any
applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
An external ventricular drainage catheter impregnated with
rifampicin, trimethoprim and triclosan, with extended activity against
MDR Gram-negative bacteria: an in vitro and in vivo study
Roger Bayston1*, Waheed Ashraf1, Ivan Pelegrin1,2, Katherine Fowkes3, Alison S. Bienemann4,
William G. B. Singleton4,5 and Ian S. Scott3
1School of Medicine, University of Nottingham, Nottingham, UK; 2Infectious Diseases Department, Hospital Universitari de Bellvitge-
IDIBELL, Barcelona, Spain; 3Department of Neuropathology, Nottingham University Hospitals NHS Trust, Nottingham, UK; 4Institute of
Clinical Neurosciences, Faculty of Health Sciences, University of Bristol, Bristol, UK; 5Department of Paediatric Neurosurgery, Bristol
Royal Hospital for Children, Bristol, UK
*Corresponding author. E-mail: roger.bayston@nottingham.ac.uk
Received 4 March 2019; returned 3 May 2019; revised 3 June 2019; accepted 11 June 2019
Background: External ventricular drainage (EVD) carries a high risk of ventriculitis, increasingly caused by MDR
Gram-negative bacteria such as Escherichia coli and Acinetobacter baumannii. Existing antimicrobial EVD cathe-
ters are not effective against these, and we have developed a catheter with activity against MDR bacteria and
demonstrated the safety of the new formulation for use in the brain.
Objectives: Our aim was to determine the ability of a newly formulated impregnated EVD catheters to with-
stand challengewith MDRGram-negative bacteria and to obtain information about its safety for use in the CNS.
Methods: Catheters impregnated with three antimicrobials (rifampicin, trimethoprim and triclosan) were chal-
lenged in flow conditions at four weekly timepoints with high doses of MDR bacteria, including MRSA and
Acinetobacter, and monitored for bacterial colonization. Catheter segments were also inserted intracerebrally
into Wistar rats, which were monitored for clinical and behavioural change, and weight loss. Brains were
removed after either 1week or 4weeks, and examined for evidence of inflammation and toxicity.
Results: Control catheters colonized quickly after the first challenge, while no colonization occurred in the
impregnated catheters even after the 4week challenge. Animals receiving the antimicrobial segments behaved
normally and gained weight as expected. Neurohistochemistry revealed only surgical trauma and no evidence
of neurotoxicity.
Conclusions: The antimicrobial catheter appears to withstand bacterial challenge for at least 4weeks, suggest-
ing that it might offer protection against infection with MDR Gram-negative bacteria in patients undergoing EVD.
It also appears to be safe for use in the CNS.
Introduction
External ventricular drainage (EVD) of CSF is widely used as a tem-
porarymeasure in themanagement of raised intracranial pressure
associated with a variety of conditions including trauma, haemor-
rhage, hydrocephalus, infection management and tumours.
Patients requiring EVD are often in intensive care. Ventriculitis is a
major complication of EVD. The reported incidence varies greatly,
from 7.8% to 27%,1–3 but is usually 5%–10% of episodes. The vari-
ation in incidence can be due to differences in patient populations,
EVDmanagement regimens and particularly diagnostic criteria.
Many regimens have been proposed to reduce the rate of ven-
triculitis associated with EVD, ranging from antibiotic prophylaxis
to ‘bundles’ of interventions.While the former shows somebenefit,
but a tendency to provoke resistance, bundles usually bring about
a reduction in infection rates, but depend on sustained compli-
ance, rates rising again after some time.4 Some changes have
brought about clear benefit, such as tunnelling of the catheter and
restricting CSF aspiration to that clinically necessary. However, fol-
lowing from the successful use of antimicrobial catheters in shunt-
ing, similar catheters have been introduced for EVD.1,3,5–7 Our
catheters containing rifampicin and clindamycin (Bactiseal,
Integra Life Sciences, Plainsboro, NJ, USA) have been successful in
reducing staphylococcal infection,8 but they have no activity
against Gram-negative bacteria. Though staphylococci are
VC The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
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traditionally themain pathogens, recently there have been reports
of increasing proportions of Gram-negative bacteria causing ven-
triculitis9–11 with an increase in multiresistance to antibiotics.10–12
Acinetobacter baumannii, Klebsiella pneumoniae and Enterobacter
spp. are themost commonly found Gram-negative bacteria. Using
similar platform technology, we have developed an EVD catheter
that retains activity against staphylococci while also having activity
against most Gram-negative EVD pathogens, including MDR
strains. The antimicrobials in the new catheter, rifampicin, tri-
methoprim and triclosan, were chosen partly for their antimicro-
bial spectrum and partly because of their chemical compatibility
with the impregnation process. As well as reporting the in vitro ac-
tivity of the catheter against these bacteria in rigorous clinically
predictive tests, we have investigated the safety of the new cath-
eter formulation for implantation into the brain using a ratmodel.
Methods
Processing of catheters
The method used was based on that already published.13 Briefly, medical
grade silicone EVD catheter tubing (Vesta Inc., Franklin, WI, USA) ID
1.5mm, OD 3.0mm, was cut to 35cm lengths. A solution of rifampicin
(0.2%), trimethoprim (1%) and triclosan (1%) in chloroform was prepared
and the catheter tubingwas immersed in the solution at room temperature
(22C) for 1h. The tubing was then removed and held in a current of air
for 18h for the solvent to evaporate. It was then briefly rinsed in ethanol
to remove any surface drug accretions, dried and packaged, and sterilized
by autoclaving at 121C for 15min. After sterilizing, three of the catheters
were selected for quality assessment. They were immersed in chloroform
for 1h at room temperature to extract antimicrobials, then the extracts
were analysed byHPLC-MS to confirmdrug content.
Test strains
All 17 bacteria tested were clinical isolates. They were: MRSA NB881,
Escherichia coli NB2203 and NB2365, Enterobacter cloacae NB1454C and
K. pneumoniae NB914 and F3990; a series of MDR strains: A. baumannii
NB893, F1865, F2653 and F3859, E. coli F3986 (ESBL producing) and E. coli
F3802 (NDM-1 producing); and a series of isolates from clinical cases where
the rifampicin/clindamycin (Bactiseal) catheter had failed due to intrinsic
resistance to either rifampicin or clindamycin or both: methicillin-resistant
Staphylococcus epidermidis NB951, NB928, NB935 and F2364, and
Staphylococcus aureus (MRSA) F1836. Their characteristics are shown in
Table S1 (available as Supplementary data at JAC Online). The MICs of ri-
fampicin and trimethoprim were determined using Etest (bioMe´rieux,
Basingstoke, UK). The MIC of triclosan was determined by microtitre plate
serial dilution.
In vitro challenge
Antimicrobial and control EVD catheters were inserted aseptically into a
modular challenge apparatus with capacity for 12 catheters to be tested
simultaneously.13,14 The apparatus determines the ability of impregnated
catheter tubing towithstandmultiple bacterial challenges in flowconditions.
The cathetersweremaintained at 37Cwhile being perfused constantly
with 20%, or 2% for Acinetobacter, tryptone soy broth (TSB; Oxoid Ltd,
Basingstoke, UK) at a rate of 20mL/h. At four timepoints (Days 0, 7, 14 and
21), the catheters were inoculated with 1mL of 105 cfu/mL suspension of
the test bacteria. For each inoculation, flowwas stopped and the catheters
clamped, and, after injection of the inoculum into the test catheter, they
remained clamped for 1h to encourage bacterial attachment. A control
catheter was set up for each test strain at each challenge, and changed
when it became colonized. Each day, a sample of TSB was collected from
each catheter, and viable cell countingwasperformed to determine bacter-
ial numbers, by spreading 200lL on a blood agar plate and incubating at
37C for 48h. All were tested in triplicate. Scanning electron microscopy
was performed on segments of both control and processed catheters at
the endof the challenge cycle. Segments of catheter 1.0 cm longwere fixed
in cold acetone overnight and then cut longitudinally and dehydrated with
tetramethylsilane (Sigma–Aldrich), fixed to specimen stubs and sputter-
coatedwith gold for 300 s before examination using a Jeol JSM 6060micro-
scope (Jeol Ltd, Tokyo, Japan).
Neuroimplantation
Segments of theprocessed catheterswere cut to4mm in length, packaged
and sterilized as above. All animal work was performed in accordance with
the UK Animal Scientific Procedures Act 1986 andwas covered by both pro-
ject and personal licences that were issued by the Home Office. Animal
licences were reviewed and approved by the University of Bristol Ethics
Committee (project licence PA95E951). All efforts were made to minimize
animal use and suffering. Juvenile male Wistar rats (Harlan, UK) weighing
250+5g were group-housed in Techniplast 1500U cages with irradiated
lignocel bedding and sawdust (International Product Supplies Ltd, UK). The
study roomwas illuminated byfluorescent light set to give a cycle of 12h of
light and 12h of dark, and was air-conditioned. The ambient temperature
was held between 17C and 22C. Subjects were randomized into one of
four groups (each containing four subjects) based on duration of treatment
before sacrifice (7 and 28days). Animals were individually anaesthetized
with 2% inhaled isoflurane in oxygen in an anaesthetic chamber then
placed in a stereotactic frame (David Kopf Instruments, Tujunga, CA, USA).
Anaesthesia wasmaintained with inhaled 2% isoflurane/oxygen. The scalp
furwas clipped and skin cleaned using alcoholic chlorhexidine. Amidline in-
cision from glabella to occiput exposing the skull was made, and a 5mm
burr hole wasmade 2mmanterior and 2mm lateral to the bregma on the
right. The dura was opened and the catheter segment stereotactically
placed in the frontal lobe on a stylet to a depth of 4mm. The stylet was
removed, leaving the segment in place. Bone wax was applied where
needed for bone haemostasis, and the wound was closed with absorbable
sutures (4/0 Vicryl RapideV
R
). Intramuscular analgesia was used post-
operatively (buprenorphine, 30lg/kg) and the animals were returned to
their housingwhen recovered.
All animals were examined daily for clinical signs of toxicity or changes
in behaviour, and body weight was recorded. All numerical data were ana-
lysed using GraphPad PrismV
R
. According to the experimental protocol, any
animals that displayed signs of neurological deterioration and/or weight
loss greater that 10% of peak bodymass would be terminated by Schedule
1 killing.
Groups 1 and 3 had control catheter segments implanted, and Groups 2
and 4 had impregnated catheter segments implanted. At the predeter-
mined timepoints, animals were euthanized by anaesthetic overdose and
then perfusion-fixed with 4% paraformaldehyde (Fisher Scientific,
Loughborough, UK) in PBS (Oxoid), pH7.4.
The brains containing the catheter segments were removed and sent
for neuropathological examination. Catheterswere removed fromthe brain
post-mortem, after brain explantation and prior to neuropathological
examination.
Neuropathology
After noting the placement site, the catheter segments were removed
from the brains, which were then processed and embedded in paraffinwax
using standard laboratory protocols (PathCentre Tissue Processor: 3 day
schedule). The neuropathologist carrying out the assessment (I. S. S.) was
blind to group allocations. Sections were stained using haematoxylin and
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fibrillary acidic protein (GFAP) (Roche) (at a dilution of 1/5000), b-amyloid
precursor protein (b-APP) (Roche) (1/20000) and neurofilament protein
(NFP) (Roche) (1/50). Immunohistochemistry was performed on a Ventana
Benchmark Ultra (Roche Diagnostics) automated stainer. The slides were
dewaxed using cell conditioner 1 (Roche) at 95C for 36min and the pri-
mary antibodies were applied as follows: 24min (GFAP), 32min (NFP) and
36min (b-APP). Haematoxylin counterstain was applied for 12min. The
slides were then mounted prior to viewing (Thermo Scientific ClearVue).
Negative controls were performed by omitting the primary antibody.




Analysis of the impregnated catheters showed rifampicin
1.58mg/g, trimethoprim 18.2mg/g and triclosan 18.4mg/g, all
within the expected range.
Test strain characteristics
Table S1 shows the 17 test strains and their susceptibilities to the
three catheter drugs.
In vitro challenge
In all cases, control catheters challenged with 105 cfu/mL of the
test bacteria colonized within a few days of inoculation, showing
high bacterial counts (108 cfu/mL). None of the impregnated
catheters inoculatedwith the test bacteria became colonized after
four successive weekly challenges. All control catheters colonized
rapidly after inoculationand reached counts of108 cfu/mLwithin
6–7days of inoculation, while counts in all the impregnated cathe-
ters declined to zerowithin 3days, remaining at zero until the next
challenge. From experiment, inoculation of 200lL of effluent from
the catheters onto blood agar plates incubated for 48h was suffi-
cient to determine absence of viable bacteria. This has been con-
firmed by scanning electron microscopic examination of
impregnated catheters after 4weeks of perfusion and bacterial
challenge (Figure1a–c). No re-growth occurred in the days after
counts reached zero, nor was any resistance seen. Examples are
shown in Tables1 and2 as all resultswere essentially similar.
Neuroimplantation
Both the 1week and the 4week groups of animals remained in
good health, gaining weight as normal with no sign of neurotox-
icity and showing normal grooming. All rats fed normally through-
out. No difference was observed between the 1week and the
4week groups, or between controls and impregnated catheter
groups.Weight gain for the 4week cohort is shown in Figure S1.
Neuropathology
Sections through the catheter tracts after 1week and 4weeks
were compared histologically with both control catheters and
impregnated catheters. The results are illustrated in Figure2(a–d).
After 1week, the tracts in both control and impregnated groups
(a) (b)
(c) (d)
Figure 1. (a and b) Scanning electron micrographs (%10000) of the lumens of catheters after four weekly bacteria challenges followed by 6–7days
of perfusion. (a) Control catheter after challenge with K. pneumoniae NB914, at Day 7 of challenge 4. (b) Control catheter after challenge with MRSA
F1836, at Day 7 of challenge 4. (c) Magnification of%500. Lumen of the processed catheter after challenge with MRSA F1836, at Day 7 of challenge 4.
The lower magnification was used to enable a more extensive field. (d) Magnification of %10000. Lumen surface of (c) with no visible bacteria
remaining. No bacteria were recovered after prolonged perfusion and agar culture.
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showed tract inflammation associated with a fierce gliotic response
(GFAP; Figure2a). Stains for b-APP revealed minor axonal damage
along the margins of the tract (Figure2b). There was no subjective
difference in the extent of inflammation between the control and
impregnated groups at this stage unless there had been significant
catheter trauma. After 4weeks, the inflammatory infiltrate in the
wall of the tract had subsided and the extent of the gliotic response
was much reduced (GFAP; Figure2c). The specimens all showed re-
sidual minor axonal injury within the tract, but the surgical inflam-
mation appeared to have subsided. The inflammatory responsewas
subjectively similar in both the control and impregnated groups after
4weeks, and the surgical inflammation appeared to have resolved
in comparisonwith the 1week specimens. Exampleswere identified,
from all experimental groups, in which there was significant trau-
matic axonal injury associated with catheter implantation
(Figure2d). These cases showed tract inflammationwith diffuse cor-
tical hypoxic injury illustrated by a ‘geographical’ pattern of cortical
stainingwith b-APP and the presence of cortical ‘red’ neurons. These
effects are, most probably, secondary to traumatic vascular injury.
In these cases, the tract inflammation was directly proportional to
the extent of surgical traumaandnot the contents of the catheter.
Discussion
Silicone EVD catheters impregnated with three antimicrobials
were able to withstand successive weekly challenges with high
numbers of MDR bacteria for at least 4weeks. EVD catheters are
not commonly used formore than 3weeks. Activity against Gram-
negative bacteria would be a significant advantage for an EVD
catheter, extending its protective spectrumbeyond its proven anti-
staphylococcal activity. Though failures due to intrinsically resist-
ant strains of staphylococci in Bactiseal EVD catheters are rare,15
we have shown that the new formulation is active against those
strains too. In addition, the results suggest that itwill be equally ef-
fective against highly antibiotic-resistant strains that are now
being increasingly encountered.
Most of the test bacteria were resistant to rifampicin, as
expected. However, there is someevidence that, evenwhenno con-
ventional susceptibility is detected, rifampicin might have sublethal
effects on the bacterial cell,11 and this has been confirmed clinical-
ly.16 We were also keen to employ the Dual Drug Principle,17,18
which indicates that this combination can be expected to reduce
the likelihood of mutational resistance to any of the three drugs,
andwepreviously have demonstrated this in vitro.19
The combination of antimicrobials, and particularly the triclosan
component, has not been used in a neurosurgical setting before,
though triclosan is used safely in other clinical applications such as
biodegradable sutures20 and urinary catheter irrigation,21,22 and
has been used safely in ureteral stents23 and central venous
Table 1. Results of four weekly challenges with MRSA F1836, showing on
each challenge rising bacterial counts in the control catheter and no
growth from the antimicrobial catheters
Day 1 Day 2 Day 3 Day 6 Day 7
Day 0, challenge 1
control 3.6%104 3.9%105 7.5%106 4.8%107 4.8%108
test 1 0 0 0 0 0
test 2 0 0 0 0 0
test 3 0 0 0 0 0
Day 0, challenge 2
control 2.8%104 7.5%106 1.5%107 4.5%107 1.1%108
test 1 0 0 0 0 0
test 2 0 0 0 0 0
test 3 0 0 0 0 0
Day 0, challenge 3
control 3.9%105 3.6%106 2.5%107 2.1%107 1.0%108
test 1 0 0 0 0 0
test 2 0 0 0 0 0
test 3 0 0 0 0 0
Day 0, challenge 4
control 2.5%105 6.5%106 6.6%107 2.5%108 1.1%108
test 1 0 0 0 0 0
test 2 0 0 0 0 0
test 3 0 0 0 0 0
A value of 0 corresponds to a value that was below the lower limit of
detection.
The negative cultures remained in the antimicrobial catheters throughout
the four weekly challenges and each post-challenge perfusion (7days).
Table 2. Results of four weekly challenges with A. baumannii NB893,
showing on each challenge rising bacterial counts in the control catheter
to the point where they became obstructed by biofilm by Day 7
Day 1 Day 2 Day 3 Day 6 Day 7
Day 0, challenge 1
control 1.3%107 1.8%107 2.9%108 4.3%108 blocked
test 1 0 0 0 0 0
test 2 0 0 0 0 0
test 3 0 0 0 0 0
Day 0, challenge 2
control 2.8%107 3.2%107 2.3%107 1.9%108 blocked
test 1 80 5 0 0 0
test 2 275 65 0 0 0
test 3 65 15 0 0 0
Day 0, challenge 3
control 2.7%107 1.5%108 5.4%108 4.9%108 blocked
test 1 225 0 0 0 0
test 2 155 0 0 0 0
test 3 185 0 0 0 0
Day 0, challenge 4
control 2.7%107 3.2%107 5.0%107 1.8%108 blocked
test 1 160 0 0 0 0
test 2 115 0 0 0 0
test 3 105 0 0 0 0
A value of 0 corresponds to a value that was below the lower limit of
detection.
There was no growth from the antimicrobial catheters at 24h after the
first challenge and though cultures were positive on monitoring on Day 1
after challenges 3 and 4, and Day 2 after challenge 2, they were negative
by Day 3 and cultures remained negative thereafter in the antimicrobial
catheters throughout the four weekly challenges and each post-chal-









niversity of Bristol Library user on 17 Septem
ber 2019
catheters.24 There is also a large amount of published human toxi-
cology data on triclosan from transcutaneous, transmucousmem-
brane and oral ingestion studies showing that it is safe.25 A pig
femoral artery graft implantation study has also showed no in-
flammatory response over and above that of control catheters.26
We have previously demonstrated its lack of toxicity in the rat peri-
toneal cavity.19 We therefore implanted catheter segments into
the brains of a series of rats. Rats in the first serieswere euthanized
at 1week to determine the effect of surgical trauma, and rats in
the second serieswere euthanized at 4weeks to determine any in-
flammation or neurotoxicity that might be caused by the antimi-
crobials. Importantly, both series of rats receiving the antimicrobial
catheter segments gainedweight normally and displayed no signs
of illness throughout, and were indistinguishable in these respects
from the control animals. When explanted brains were examined
neuropathologically, though the relatively large segments caused
considerable surgical trauma, there was no evidence of inflamma-
tion or toxicity that could be attributed to the antimicrobials in the
catheter. Wewere pleased to note that US and EU regulators have
recently banned triclosan in all but medical products, recognizing
its importance and safety in this area.
Conclusions
The antimicrobial EVD catheter therefore appears to be effective
against EVD pathogens and safe for implantation into the brain.
The relatively long duration of protection against colonization by
even MDR bacteria suggests that it might be beneficial in reducing
EVD infections. Further studies will include insertion of whole cath-
eters into a large animal model and bacterial challenge in vivo. If
this study is successful, human studieswill follow.
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